A Phase 3, Double-blind Maintenance Study Assessing Rocatinlimab in Moderate-to-severe AD (ROCKET-ASCEND)

Brief summary (registry, in English)

To describe the long-term safety and tolerability of rocatinlimab in subjects with moderate-to-severe AD

What you commit to

• Study type: Interventional · Phase 3
• Participants enrolled: 615
• 192 sites in 22 countries
• Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study, not your situation.

Who cannot take part

Copied verbatim from EU CTIS (euclinicaltrials.eu) and grouped by topic. Only the trial team decides who can take part.

Who the study is looking for

Sex: All · Does not accept healthy volunteers

Full criteria on EU CTIS (euclinicaltrials.eu)

Sites (192)

Sites in registry order. Pick your city on the disease page to sort them by distance.